Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVAL: Ranibizumab vs Aflibercept in wet AMD
NCT02130024Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- Nov 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Started Apr 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02130024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130024.